Trial Profile
A Prospective, Multi-center, Open-label Study of Trospium Delivered Intravesically by TAR-302-5018 to Subjects With Idiopathic Overactive Bladder (iOAB) and Urinary Incontinence
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs TAR-302-5018 (Primary)
- Indications Mixed incontinence; Overactive bladder; Urinary incontinence
- Focus Adverse reactions
- Sponsors TARIS Biomedical
- 10 Jan 2020 Status changed from active, no longer recruiting to completed.
- 25 Jul 2019 According to a TARIS Biomedical media release, data (n=11) from this trial will be presented at the Annual Meeting of the International Continence Society (ICS) 2019.
- 22 Apr 2019 Planned number of patients changed from 10 to 40.